基于AVP-AQP2调控通路的表达研究天麻止晕散对耳性眩晕大鼠模型内耳膜迷路积水的治疗效应

Objective Based on the expression study of the vasopressin-aquaporin 2 signaling(AVP-AQP2) regulatory pathway, the therapeutic effect of Tianma Zhuyun San on the endolymphatic hydrops in the inner ear of rats with vestibular vertigo was investigated. Methods In this study, 32 SPF-grade Wistar rats were randomly divided into a blank control group, a model control group, a western medicine treatment group, and an experimental treatment group, with 8 rats in each group. Except for the blank control group, the other three groups were constructed to model otic vertigo by intraperitoneal injection of vasopressin. Subsequently, the western medicine treatment group was given fluoxymesterone hydrochloride by gavage, the experimental treatment group was given Tianma Zhuyun San by gavage, and the model control group and the blank control group were given normal saline by gavage. The intervention lasted for 10 days. The plasma arginine vasopressin(AVP) concentration was detected by ELISA method. The degree of membranous labyrinth hydrops and the expression of aquaporin 2(AQP2) in the cochlea were evaluated by image analysis. The upstream and downstream molecules and activities on the pathway were also supplemented for detection. Results The plasma AVP concentration, the ratio of the cross-sectional area of the cochlear duct to the total area, the expression of AQP2, and the activity of related pathway molecules in the model group were all significantly higher than those in the blank control group(P<0.05). The above indicators in both treatment groups were significantly reduced, and the improvement effect of the experimental treatment group was better than that of the western medicine treatment group(P<0.05). Conclusion Tianma Zhuyun San can effectively alleviate the inner ear membranous labyrinth edema in rats with vestibular vertigo by reducing plasma AVP levels, down-regulating the expression of AQP2 in the cochlea, and regulating the upstream and downstream molecules and activities of the AVP-AQP2 pathway. This provides experimental evidence for the treatment of Meniere's disease(MD).